Related references
Note: Only part of the references are listed.What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
Emiliano Calvo et al.
CANCER TREATMENT REVIEWS (2013)
The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy
Robyn Macfarlane et al.
CANCER (2012)
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
E. Calvo et al.
EUROPEAN JOURNAL OF CANCER (2012)
A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma
Nizar M. Tannir et al.
EUROPEAN UROLOGY (2012)
Histologic Variants of Renal Cell Carcinoma: Does Tumor Type Influence Outcome?
Fang-Ming Deng et al.
UROLOGIC CLINICS OF NORTH AMERICA (2012)
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
J. Beck et al.
ANNALS OF ONCOLOGY (2011)
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis
Debra Josephs et al.
BJU INTERNATIONAL (2011)
Sunitinib in Metastatic Renal Cell Carcinoma Patients With Brain Metastases
Martin E. Gore et al.
CANCER (2011)
Impact of Tyrosine Kinase Inhibitors on the Incidence of Brain Metastasis in Metastatic Renal Cell Carcinoma
Jonathan Verma et al.
CANCER (2011)
Heart Failure Associated with Sunitinib: Lessons Learned from Animal Models
Colin F. Greineder et al.
CURRENT HYPERTENSION REPORTS (2011)
Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated Cardiotoxicity
Rajesh Gupta et al.
CURRENT HYPERTENSION REPORTS (2011)
Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib
Christopher J. Richards et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America
Walter M. Stadler et al.
CANCER (2010)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function
Reza Khosravan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
G. Di Lorenzo et al.
ANNALS OF ONCOLOGY (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
Janice P. Dutcher et al.
MEDICAL ONCOLOGY (2009)
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
M. L. Telli et al.
ANNALS OF ONCOLOGY (2008)
Metastatic renal cell carcinoma: Results of a population-based study with 25 years follow-up
Anne Schlesinger-Raab et al.
EUROPEAN JOURNAL OF CANCER (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) - targeted therapy in metastatic renal cell carcinoma (RCC)
T. K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
Toni K. Choueiri et al.
CANCER (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
2004 WHO classification of the renal tumors of the adults
A Lopez-Beltran et al.
EUROPEAN UROLOGY (2006)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review
JM Peppercorn et al.
LANCET (2004)
Sample size slippages in randomised trials: exclusions and the lost and wayward
KF Schulz et al.
LANCET (2002)
Are randomized clinical trials good for us (in the short term)? Evidence for a trial effect
DA Braunholtz et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
